中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

已选(0)清除 条数/页：   排序方式：
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) 期刊论文
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 卷号: 897
作者:  Lu, Tingting;  Cao, Jiangyan;  Zou, Fengming;  Li, Xixiang;  Wang, Aoli;  Wang, Wenliang;  Liang, Huamin;  Liu, Qingwang;  Hu, Chen;  Chen, Cheng;  Hu, Zhenquan;  Wang, Wenchao;  Li, Lili;  Ge, Jian;  Shen, Yang;  Ren, Tao;  Liu, Jing;  Xia, Ruixiang;  Liu, Qingsong
收藏  |  浏览/下载：80/0  |  提交时间：2021/04/26
BCR-ABL  ABL mutants  Chronic myeloid leukemia  Kinase inhibitor  Imatinib resistance  
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino) cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl) tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 158, 页码: 896-916
作者:  Wang, Beilei;  Wu, Jiaxin;  Wu, Yun;  Chen, Cheng;  Zou, Fengming;  Wang, Aoli;  Wu, Hong;  Hu, Zhenquan;  Jiang, Zongru;  Liu, Qingwang;  Wang, Wei;  Zhang, Yicong;  Liu, Feiyang;  Zhao, Ming;  Hu, Jie;  Huang, Tao;  Ge, Juan;  Wang, Li;  Ren, Tao;  Wang, Yuxin;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：28/0  |  提交时间：2019/12/25
CDK9  Kinase inhibitor  Structure-activity relationship  Leukemia